Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer

Purpose To evaluate the efficacy and safety profile of the combination of panitumumab and irinotecan every 3 weeks in a phase II trial as second-line treatment in patients with advanced wild-type (WT) K-RAS colorectal cancer (CRC). Methods Fifty-three patients received 9 mg/kg of panitumumab followe...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical & translational oncology Vol. 15; no. 9; pp. 705 - 711
Main Authors:	Carrato, A., Gómez, A., Escudero, P., Chaves, M., Rivera, F., Marcuello, E., González, E., Grávalos, C., Constenla, M., Manzano, J. Luis, Losa, F., Maurel, J., Dueñas, R., Massuti, B., Gallego, J., Aparicio, J., Antón, A., Aranda, E.
Format:	Journal Article
Language:	English
Published:	Milan Springer Milan 01-09-2013
Subjects:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antineoplastic Agents - administration & dosage Antineoplastic Agents, Phytogenic - administration & dosage Camptothecin - administration & dosage Camptothecin - analogs & derivatives Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Disease-Free Survival Drug Administration Schedule Female Genes, ras Humans Male Medicine Medicine & Public Health Middle Aged Oncology Prospective Studies ras Proteins - metabolism Research Article Time Factors Treatment Outcome Monoclonal antibodies Topoisomerase I inhibitors Epidermal growth factor receptor (EGFR) inhibitors Colorectal cancer Prospective trial
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Purpose To evaluate the efficacy and safety profile of the combination of panitumumab and irinotecan every 3 weeks in a phase II trial as second-line treatment in patients with advanced wild-type (WT) K-RAS colorectal cancer (CRC). Methods Fifty-three patients received 9 mg/kg of panitumumab followed by 350 mg/m 2 of irinotecan every 21 days until disease progression, unacceptable toxicity or consent withdrawal. Results Median age of patients included was 67 years. All patients had previously received 5-fluorouracil, 84 % oxaliplatin and 8 % irinotecan as first-line treatment. Patients received a median of five infusions of panitumumab and irinotecan. On an intention-to-treat analysis, 12 patients (23 %) achieved partial responses and 22 patients (41 %) achieved disease stabilization. Median progression-free survival and overall survival were 4.5 and 15.1 months, respectively. The most frequent treatment-related severe toxicities per patient were diarrhoea (35.8 %), followed by skin rash (32.1 %), asthenia (18.9 %) and neutropenia (13.2 %). A significant association between clinical response and incidence and grade of skin toxicity was observed ( p = 0.0032). Conclusion This study shows that the administration of panitumumab plus irinotecan every 3 weeks is safe, active and feasible as second-line treatment in patients with advanced WT K-RAS CRC.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	1699-048X 1699-3055
DOI:	10.1007/s12094-012-0993-x